BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Biomarin Pharmaceutical Inc's non-recurring items for the three months ended in Jun. 2016 was $-1.6 Mil. Its non-recurring items for the trailing twelve months (TTM) ended in Jun. 2016 was $-16.8 Mil.
As of today, Biomarin Pharmaceutical Inc's share price is $92.81. Biomarin Pharmaceutical Inc's earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2016 was $-3.30. Therefore, Biomarin Pharmaceutical Inc's P/E (NRI) ratio for today is .
Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Examples of NRI include gains (losses) from plant shutdown, lease-breaking fees, lawsuit, write-offs, write-downs, restructuring costs or sales of an investment, discontinued operations etc.
NRI can impact a companys reported income drastically.
Biomarin Pharmaceutical Inc Non-Recurring Items for the trailing twelve months (TTM) ended in Jun. 2016 was -7.631 (Sep. 2015 ) + -7.722 (Dec. 2015 ) + 0.063 (Mar. 2016 ) + -1.552 (Jun. 2016 ) = $-16.8 Mil.
GuruFocus lists a P/E (NRI), which is the price/earnings before NRI. We believe it more accurately reflects the valuation of the company.
Biomarin Pharmaceutical Inc's P/E (NRI) Ratio for today is calculated as
Biomarin Pharmaceutical Inc's Share Price of today is $92.81.
Biomarin Pharmaceutical Inc's Earnings per Share (NRI) for the trailing twelve months (TTM) ended in Jun. 2016 was -0.6 (Sep. 2015 ) + 0.44 (Dec. 2015 ) + -0.53 (Mar. 2016 ) + -2.61 (Jun. 2016 ) = $-3.30.
Biomarin Pharmaceutical Inc Annual Data
|Non Operating Income||19.3||30.5||-6.3||-6.9||-15.3||-4.3||-3.0||-19.0||-28.5||-38.8|
Biomarin Pharmaceutical Inc Quarterly Data
|Non Operating Income||-6.9||-1.4||-7.1||-6.3||-0.1||-9.3||-7.6||-7.7||0.1||-1.6|
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.